PMID- 29778806
OWN - NLM
STAT- MEDLINE
DCOM- 20180920
LR  - 20181202
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 207
DP  - 2018 Aug 15
TI  - Evaluation of antioxidant potencial of novel CaAl and NiAl layered double 
      hydroxides loaded with olanzapine.
PG  - 246-252
LID - S0024-3205(18)30294-7 [pii]
LID - 10.1016/j.lfs.2018.05.031 [doi]
AB  - Olanzapine (OLZ), is used in the treatment of bipolar disorder and schizophrenia, 
      diseases that present oxidative stress in their physiopathology. It has low 
      aqueous solubility, which may lead to low oral bioavailability. The search of new 
      drug delivery systems (DDSs) that may increase dissolution rate of OLZ, 
      associated with the investigation of the antioxidant potential of the 
      loaded-systems become of major importance to understand improvement in bipolar 
      disorder and schizophrenia therapy. Thus, this study aimed to evaluate the in 
      vitro antioxidant potential of two different Layered Double Hydroxides (LDH) 
      loaded with 5% of OLZ (CaAl and NiAl), by radical scavenging activity 
      (2,2-Diphenyl-1-picrylhydrazyl and nitric oxid); radical cation scavenging 
      activity (2,2'-azino-bis3-ethylbenzthiazoline-6-sulfonic acid ABTS) and 
      evaluation of inhibition capacity of lipid peroxidation by thiobarbituric acid 
      (TBARS). The results showed that both obtained LDH systems presented in vitro 
      antioxidant capacity when associated with OLZ in all methods performed, and this 
      activity is more pronounced with the systems containing OLZ compared to pure 
      drug. The systems with CaAl was shown to have increased antioxidant potential, 
      compared to NiAl, increasing the antioxidant activity up to 40,83%, 15,84% and 
      16,73%, as showed by the DPPH, nitric oxide and TBARS tests, respectively. The 
      results revealed that the use of LDHs as a functional excipient may be promising 
      in the pharmaceutical industry for bipolar disorder and schizophrenia therapy.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Pontes-Neto, Joao Gomes
AU  - Pontes-Neto JG
AD  - Nucelo de Controle de Qualidade de Medicamentos e Correlatos, Universidade 
      Federal de Pernambuco, Recife, PE, Brazil.
FAU - Fontes, Danilo Augusto Ferreira
AU  - Fontes DAF
AD  - Laboratorio de Tecnologia de Medicamentos, Universidade Federal de Pernambuco, 
      Recife, PE, Brazil.
FAU - de Lyra, Magaly Andreza Marques
AU  - de Lyra MAM
AD  - Nucelo de Controle de Qualidade de Medicamentos e Correlatos, Universidade 
      Federal de Pernambuco, Recife, PE, Brazil.
FAU - Brito, Maria Dos Remedios Mendes de
AU  - Brito MDRM
AD  - Laboratorio de Neuroquimica Experimental, Universidade Federal do Piaui, 
      Teresina, PI, Brazil.
FAU - Chaves, Luise Lopes
AU  - Chaves LL
AD  - Laboratorio Interdisciplinar de Materiais Avancados - LIMAV, Programa de 
      Pos-Graduacao em Ciencias dos Materiais, Universidade Federal do Piaui.
FAU - Rolim-Neto, Pedro Jose
AU  - Rolim-Neto PJ
AD  - Laboratorio de Tecnologia de Medicamentos, Universidade Federal de Pernambuco, 
      Recife, PE, Brazil.
FAU - De La Roca Soares, Monica Felts
AU  - De La Roca Soares MF
AD  - Nucelo de Controle de Qualidade de Medicamentos e Correlatos, Universidade 
      Federal de Pernambuco, Recife, PE, Brazil.
FAU - Quintans Junior, Lucindo Jose
AU  - Quintans Junior LJ
AD  - Departamento de Fisiologia, Universidade Federal de Sergipe, Aracaju, SE, Brazil.
FAU - de Freitas, Rivelilson Mendes
AU  - de Freitas RM
AD  - Laboratorio de Neuroquimica Experimental, Universidade Federal do Piaui, 
      Teresina, PI, Brazil.
FAU - Soares-Sobrinho, Jose Lamartine
AU  - Soares-Sobrinho JL
AD  - Laboratorio de Tecnologia de Medicamentos, Universidade Federal de Pernambuco, 
      Recife, PE, Brazil. Electronic address: joselamartine@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20180517
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Antioxidants)
RN  - 0 (Excipients)
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Hydroxides)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 7OV03QG267 (Nickel)
RN  - CPD4NFA903 (Aluminum)
RN  - N7U69T4SZR (Olanzapine)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Aluminum/*chemistry
MH  - Antioxidants/*chemistry
MH  - Benzodiazepines/*chemistry
MH  - Bipolar Disorder/drug therapy
MH  - Calcium/*chemistry
MH  - Drug Delivery Systems
MH  - Excipients/chemistry
MH  - Free Radical Scavengers
MH  - Humans
MH  - Hydroxides/*chemistry
MH  - Lipid Peroxidation
MH  - Nickel/*chemistry
MH  - Olanzapine
MH  - Oxidative Stress/drug effects
MH  - Schizophrenia/drug therapy
MH  - Thiobarbituric Acid Reactive Substances/chemistry
OTO - NOTNLM
OT  - Bipolar disorder
OT  - Drug Delivery Systems
OT  - Free radical
OT  - Inorganic systems
OT  - Schizophrenia treatment
EDAT- 2018/05/21 06:00
MHDA- 2018/09/21 06:00
CRDT- 2018/05/21 06:00
PHST- 2018/03/22 00:00 [received]
PHST- 2018/05/09 00:00 [revised]
PHST- 2018/05/16 00:00 [accepted]
PHST- 2018/05/21 06:00 [pubmed]
PHST- 2018/09/21 06:00 [medline]
PHST- 2018/05/21 06:00 [entrez]
AID - S0024-3205(18)30294-7 [pii]
AID - 10.1016/j.lfs.2018.05.031 [doi]
PST - ppublish
SO  - Life Sci. 2018 Aug 15;207:246-252. doi: 10.1016/j.lfs.2018.05.031. Epub 2018 May 
      17.